How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) has been drawing attention after recent trading, with the stock closing at $4.67. Investors are weighing this price against the company’s clinical pipeline and ongoing ...

CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...